English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The σ 2 receptor is a potential in vivo target for measuring proliferative status in cancer. The feasibility of using N -(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1 H )-yl)butyl)-2-(2- 18 F-fluoroethoxy)-5-methylbenzamide ( 18 F-ISO-1) to image solid tumors in lymphoma, breast cancer, and head and neck cancer has been previously established. Here, we report the results of the first dedicated clinical trial of 18 F-ISO-1 in women with primary breast cancer. Our study objective was to determine whether 18 F-ISO-1 PET could provide an in vivo measure of tumor proliferative status, and we hypothesized that uptake would correlate with a tissue-based assay of proliferation, namely Ki-67 expression. Methods: Twenty-eight women with 29 primary invasive breast cancers were prospectively enrolled in a clinical trial (NCT02284919) between March 2015 and January 2017. Each received an injection of 278-527 MBq of 18 F-ISO-1 and then underwent PET/CT imaging of the breasts 50-55 min later. In vivo uptake of 18 F-ISO-1 was quantitated by SUV max and distribution volume ratios and was compared with ex vivo immunohistochemistry for Ki-67. Wilcoxon rank-sum tests assessed uptake differences across Ki-67 thresholds, and Spearman correlation tested associations between uptake and Ki-67. Results: Tumor SUV max (median, 2.0 g/mL; range, 1.3-3.3 g/mL), partial-volume-corrected SUV max , and SUV ratios were tested against Ki-67. Tumors stratified into the high-Ki-67 (≥20%) group had SUV max greater than the low-Ki-67 (&lt;20%) group ( P = 0.02). SUV max exhibited a positive correlation with Ki-67 across all breast cancer subtypes (ρ = 0.46, P = 0.01, n = 29). Partial-volume-corrected SUV max was positively correlated with Ki-67 for invasive ductal carcinoma (ρ = 0.51, P = 0.02, n = 21). Tumor-to-normal-tissue ratios and tumor distribution volume ratio did not correlate with Ki-67 ( P &gt; 0.05). Conclusion:  18 F-ISO-1 uptake in breast cancer modestly correlates with an in vitro assay of proliferation.

Breast Cancer18F-ISO-1 Uptake as a Marker of Proliferation Status

Breast Cancer¹⁸F-ISO-1 Uptake as a Marker of Proliferation Status